Response‑adapted involved site radiation therapy for hepatic marginal zone B‑cell lymphoma: A case report

Chen,Shin-Ting; Chen,Yu-Guang; Huang,Wen-Yen; Lo,Cheng-Hsiang

doi:10.3892/ol.2025.14934

Response‑adapted involved site radiation therapy for hepatic marginal zone B‑cell lymphoma: A case report

Authors:
- Shin-Ting Chen
- Yu-Guang Chen
- Wen-Yen Huang
- Cheng-Hsiang Lo
View Affiliations

Affiliations: Department of Radiation Oncology, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C., Division of Hematology/Oncology, Department of Internal Medicine, Tri‑Service General Hospital, National Defense Medical Center, Taipei 114, Taiwan, R.O.C.
Published online on: February 13, 2025 https://doi.org/10.3892/ol.2025.14934
Article Number: 188
Copyright: © Chen et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Hepatic marginal zone B‑cell lymphoma (MZL) is a rare and challenging entity that is often misinterpreted as hepatocellular carcinoma owing to its non‑specific radiological features. The current case report details the clinical presentation, diagnosis and treatment of an older adult female with hepatic MZL involving both lobes, complicated by Sjögren's syndrome and common variable immunodeficiency. Given the patient's immunodeficiency and the risks associated with chemotherapy, involved site radiotherapy (ISRT) was administered as the primary treatment. Using a response‑adapted approach, an initial radiotherapy dose of 24 Gy over 16 fractions was delivered to the major hepatic lesion, followed by a local boost to both lobes after significant tumor shrinkage. The patient tolerated the treatment well with minimal side effects, and post‑treatment imaging showed a complete metabolic response. This case highlights the effectiveness of response‑adapted ISRT in managing hepatic MZL in immunocompromised patients and underscores the need for individualized treatment approaches for rare lymphomas.

View Figures

View References

1	Cerhan JR and Habermann TM: Epidemiology of marginal zone. Lymphoma. Ann Lymphoma. 5:2021. View Article : Google Scholar : PubMed/NCBI
2	Chuang SS, Chen SW, Chang ST and Kuo YT: Lymphoma in Taiwan: Review of 1347 neoplasms from a single institution according to the 2016 Revision of the World Health Organization Classification. J Formos Med Assoc. 116:620–625. 2017. View Article : Google Scholar : PubMed/NCBI
3	El-Fattah MA: Non-hodgkin lymphoma of the liver: A US population-based analysis. J Clin Transl Hepatol. 5:83–91. 2017.PubMed/NCBI
4	Zucca E, Arcaini L, Buske C, Johnson PW, Ponzoni M, Raderer M, Ricardi U, Salar A, Stamatopoulos K, Thieblemont C, et al: Marginal zone lymphomas: ESMO clinical practice guidelines. Ann Oncol. 31:17–29. 2020. View Article : Google Scholar : PubMed/NCBI
5	Routsias JG, Goules JD, Charalampakis G, Tzima S, Papageorgiou A and Voulgarelis M: Malignant lymphoma in primary Sjögren's syndrome: An update on the pathogenesis and treatment. Semin. Arthritis Rheum. 43:178–186. 2013.PubMed/NCBI
6	Smith T and Cunningham-Rundles C: Lymphoid malignancy in common variable immune-deficiency in a single-center cohort. Eur J Haematol. 107:503–516. 2021. View Article : Google Scholar : PubMed/NCBI
7	Amin MB, Edge SB, Greene FL, Byrd DR, Brookland RK, Washington MK, Gershenwald JE, Compton CC, Hess KR, Sullivan DC, et al: AJCC Cancer Staging Manual. 8th Edition. Springer Cham; Switzerland: pp. 9542017
8	U.S. Department of Health and Human Services, . Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. https://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03/Archive/CTCAE_4.0_2009-05-29_QuickReference_8.5×11.pdfFebruary 12–2025
9	Meignan M, Gallamini A, Meignan M, Gallamini A and Haioun C: Report on the first international workshop on interim-PET-scan in lymphoma. Leuk Lymphoma. 50:1257–1260. 2009. View Article : Google Scholar : PubMed/NCBI
10	Zucca E, Bertoni F, Vannata B and Cavalli F: Emerging role of infectious etiologies in the pathogenesis of marginal zone B-cell lymphomas. Clin Cancer Res. 20:5207–5216. 2014. View Article : Google Scholar : PubMed/NCBI
11	Betianu CI, Dima A and Pavaloiu G: Primary hepatic mucosa-associated lymphoid tissue lymphoma in a patient with no chronic liver disease: Case report. J Radiol Case Rep. 12:715–719. 2017. View Article : Google Scholar : PubMed/NCBI
12	Bao C, Wei J, Zhao X, Lin L, Chen D, Liu K, Qian W, Anas JM and Zhao K: Prognostic value of fluorine-18-fluorodeoxyglucose positron emission tomography/computed tomography in primary hepatic mucosa-associated lymphoid tissue lymphoma: A case report and review of the literature. Medicine (Baltimore). 97:98772018. View Article : Google Scholar
13	Choi S, Kim JH, Kim K, Kim M, Choi HJ, Kim YM, Suh JH, Seo MJ and Cha HJ: Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue. J Pathol Transl Med. 54:340–345. 2020. View Article : Google Scholar : PubMed/NCBI
14	Okura K, Seo S, Shimizu H, Nishino H, Yoh T, Fukumitsu K, Ishii T, Hata K, Haga H and Hatano E: Primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue lymphoma treated by laparoscopic partial hepatectomy: A case report. Surg Case Rep. 9:292023. View Article : Google Scholar : PubMed/NCBI
15	Xu Z, Pang C, Sui J and Gao Z: A case of primary hepatic extranodal marginal zone B-cell mucosa-associated lymphoid tissue (MALT) lymphoma treated by radiofrequency ablation (RFA), and a literature review. J Int Med Res. 49:300060521999539. 2021.
16	Yamashita Y, Joshita S, Kobayashi H, Wakabayashi SI, Sugiura A, Yamazaki T and Umemura T: Primary hepatic extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue in a patient with chronic hepatitis B virus infection: Case report and summary of the literature. Medicina (Kaunas). 57:2802021. View Article : Google Scholar : PubMed/NCBI
17	Xie H, Lv J, Ji Y, Du X and Yang X: Primary hepatic mucosa-associated lymphoid tissue lymphoma. Medicine (Baltimore). 98:e150342019. View Article : Google Scholar : PubMed/NCBI
18	Koh HD, Choi JW, Kim EK, Park S, Kim MJ and Lee CK: Primary hepatic mucosa-associated lymphoid tissue lymphoma mimicking hepatocellular carcinoma in a patient with chronic hepatitis B: A case report. J Int Med Res. 51:30006052311543992023. View Article : Google Scholar : PubMed/NCBI
19	Liu C, Liu Y, Zhang J, Chai Y, Lu B and Tang H: Primary hepatic mucosa-associated lymphoid tissue lymphoma complicated with atrial fibrillation: A case report and literature review. Medicine (Baltimore). 103:e369262024. View Article : Google Scholar : PubMed/NCBI
20	Benson AB III, D'Angelica MI, Abrams T, Ahmed A, Anaya DA, Anders R, Are C, Bachini M, Baker M, Binder D, et al: NCCN clinical practice guidelines in oncology: Hepatocellular carcinoma. National Comprehensive Cancer Network, Version. 1:512024.
21	Zelenetz AD, Gordon LI, Abramson JS, Advani RH, Andreadis B, Bartlett NL, Budde LE, Caimi PF, Chang JE, Christian B, et al: NCCN clinical practice guidelines in oncology: B-cell lymphomas. National Comprehensive Cancer Network, Version. 2:1442024.
22	Pinnix CC, Dabaja BS, Gunther JR, Fang PQ, Wu SY, Nastoupil LJ, Strati P, Nair R, Ahmed S, Steiner R, et al: Response-adapted ultralow-dose radiation therapy for orbital indolent B-Cell lymphoma A phase 2 nonrandomized controlled trial. JAMA Oncol. 10:1195–1203. 2024. View Article : Google Scholar : PubMed/NCBI
23	Yahalom J, Illidge T, Specht L, Hoppe RT, Li YX, Tsang R and Wirth A; International Lymphoma Radiation Oncology Group, : Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the international lymphoma radiation oncology group. Int J Radiat Oncol Biol Phys. 92:11–31. 2015. View Article : Google Scholar : PubMed/NCBI
24	Toesca DAS, Ibragimov B, Koong AJ, Xing L, Koong AC and Chang DT: Strategies for prediction and mitigation of radiation-induced liver toxicity. J Radiat Res. 59:40–49. 2018. View Article : Google Scholar
25	Toesca DA, Osmundson EC, Eyben RV, Shaffer JL, Lu P, Koong AC and Chang DT: Central liver toxicity after SBRT: An expanded analysis and predictive nomogram. Radiother Oncol. 122:130–136. 2017. View Article : Google Scholar : PubMed/NCBI
26	Katano A and Yamashita H: Definitive radiotherapy for stage I gastric mucosa-associated lymphoid tissue lymphoma: A retrospective cohort of unique-dose administration of 30 Gy in 15 fractions and analysis of remission duration. World J Oncol. 15:506–510. 2024. View Article : Google Scholar : PubMed/NCBI